Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression
Dr Shanu Modi talks to ecancer about her findings from a phase 3 randomised study, known as DESTINY-Breast04, investigating trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-low unresectable and or metastatic breast cancer.
She discusses and outlines the methodology of the study.
Then goes onto to explain the results and key findings which were that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.
Видео Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression канала ecancer
She discusses and outlines the methodology of the study.
Then goes onto to explain the results and key findings which were that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.
Видео Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression канала ecancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metas...](https://i.ytimg.com/vi/D5CBf8TI_44/default.jpg)
![Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC](https://i.ytimg.com/vi/vPhDzTjFnPw/default.jpg)
![Breast cancer prevention in high-risk post-menopausal women](https://i.ytimg.com/vi/SfEoJpiaXpM/default.jpg)
![Regional lymph node irradiation in early breast cancer](https://i.ytimg.com/vi/06w_bZGQlE8/default.jpg)
![Latest advances in mHSPC from ASCO GU 2020](https://i.ytimg.com/vi/thniCdBdCvU/default.jpg)
![ESMO 2017: Prostate cancer highlights](https://i.ytimg.com/vi/-K-QwyjMLmM/default.jpg)
![Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans](https://i.ytimg.com/vi/e6n7qAUq7bE/default.jpg)
![Breast cancer highlights from ASCO 2019](https://i.ytimg.com/vi/i-ec1vlYHM4/default.jpg)
![The CAR T cell revolution in cancer therapy](https://i.ytimg.com/vi/LpKmD8Qz--0/default.jpg)
![Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients](https://i.ytimg.com/vi/G60tqTLawqA/default.jpg)
![CLL14: Venetoclax plus obinutuzumab in untreated CLL](https://i.ytimg.com/vi/pZzj0wjfVBg/default.jpg)
![Prostate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from...](https://i.ytimg.com/vi/gfpI8GlwgxE/default.jpg)
![Managing the side effects of CAR T-cell therapy](https://i.ytimg.com/vi/6k78iS43Eko/default.jpg)
![LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RT](https://i.ytimg.com/vi/oYh3Vx2rcyw/default.jpg)
![Maintenance chemotherapy extends life for children with rare rhabdomyosarcoma](https://i.ytimg.com/vi/nEleWQKjpxU/default.jpg)
![Advances in prostate cancer in the last 10 years and a glimpse to the future](https://i.ytimg.com/vi/2Mvm24ne2VE/default.jpg)
![Holistic management of patients with ALK-positive NSCLC](https://i.ytimg.com/vi/mu0L4vvKSII/default.jpg)
![Master pathways and targets in T cell acute lymphoblastic leukaemia](https://i.ytimg.com/vi/uuzScxD7-Xs/default.jpg)
![Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts](https://i.ytimg.com/vi/VqL36BNlMZw/default.jpg)
![The role of lymph nodes in stage 3 lung cancer](https://i.ytimg.com/vi/C16LtmLwrAc/default.jpg)
![Stereotactic body radiotherapy compared with surgery for localised prostate cancer](https://i.ytimg.com/vi/Kwc0bymr2Dc/default.jpg)